Primary adrenal insufficiency (PAI), a rare and potentially life-threatening disorder, involves genetic factors in over 80% of pediatric cases. Congenital adrenal hyperplasia (CAH) is common, while the prevalence of other genetic factors varies between countries.

Using the manufacturer's suggested cutoff values for anti-glutamic acid decarboxylase antibodies (GADA) results in intermediate levels (1-2U/mL) in which the patient's status is unclear. Our aim was to re-evaluate these thresholds by characterizing patient phenotype according to GADA level.

Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is a rare tumor, but with increasing global prevalence. However, data on epidemiology and survival in Latin America are sparse.

Hypogonadism has been reported in patients with X-linked adrenoleukodystrophy (ALD), but little is known about prevalence and characteristics. We aimed to further characterize hypogonadism in males with ALD.

Over the past two decades, interventional techniques in cervical endocrine pathology have evolved significantly, offering less invasive alternatives to conventional surgery. This update reviews the latest advances in non-surgical approaches, including percutaneous ethanol injection (PEI) and thermal ablation (TA), with a focus on their indications, efficacy, and safety profiles. PEI remains the treatment of choice for cystic thyroid nodules. The technique involves ethanol-induced tissue necrosis, leading to significant nodule shrinkage. PEI is simple to perform, with a low risk of major complications, though transient local pain is a common minor side effect. Thermal-ablation, encompassing radiofrequency ablation (RFA), laser ablation (LA), and microwave ablation (MWA), utilizes thermal energy to induce controlled tissue necrosis. It has become a well-established option for benign solid and mixed thyroid nodules, and in selected cases, for autonomously functioning thyroid nodules. Increasing evidence also supports its role in the management of low-risk papillary thyroid carcinoma, demonstrating favorable oncologic outcomes. TA is now recognized as a viable alternative for locoregional recurrent thyroid cancer, particularly in patients at high surgical risk or those who refuse surgery. Its use ranges from curative to palliative intent, depending on disease extent and patient factors. For parathyroid adenomas, TA may be considered a first-line treatment for intrathyroidal adenomas, avoiding unnecessary thyroid lobectomy. In exceptional cases, it may serve as a second-line therapy for patients who are either ineligible for surgery or opt against it. These minimally invasive techniques continue to gain prominence, broadening their indications and refining procedural protocols. This update underscores their role in modern endocrine practice, aiming to optimize patient outcomes while preserving thyroid and parathyroid function.

The triglyceride-glucose (TyG) index has been proposed as a reliable surrogate marker of insulin resistance. Correlation with mortality has produced inconsistent results in studies involving different populations. The present study used data from a large prospective cohort study to evaluate the association of TyG index with all-cause and cause-specific mortality and potential influencing factors, particularly exploring associations and correlations with mortality of thresholds in different subgroups of the population.

Several putative susceptibility genes for familial papillary thyroid carcinoma, or familial non-medullary thyroid carcinoma (FNMTC), have been identified. However, in most families the molecular basis for FNMTC remains elusive.

In 2024, the French Society of Endocrinology, the French-speaking Association of Endocrine Surgery, and the French Society of Nuclear Medicine have elaborated a joint consensus statement on primary hyperparathyroidism, which was presented at the last congress of the French Society of Endocrinology, in October 2024, and subsequently published as 15 individual chapters in the Annals of Endocrinology. This consensus statement is a fruit of a joint effort by over 80 French-speaking experts in the field, including adult and pediatric endocrinologists, endocrine and pediatric surgeons, radiologists, nuclear medicine specialists, biologists and geneticists, and has been endorsed by the Belgian and Swiss endocrine societies. This document summarizes the recommendations, subdivided into 15 sections each preceded by a brief introduction. It aimed at covering systematically all areas of diagnosis and management of primary hyperparathyroidism throughout life in a comprehensive way, that we hope could be useful in particular to our younger colleagues in training.

Lipodystrophy syndromes are rare diseases characterized by anatomical and functional defects of adipose tissue, frequently leading to severe insulin resistance-associated metabolic complications. Subtypes of lipodystrophy syndromes differ in: their clinical presentation, with generalized or partial loss of adipose tissue; in their origin, either genetic or acquired; and in their comorbidities, forming a heterogeneous group of disorders of different severity. The European Consortium of Lipodystrophies (ECLip) was founded in 2014 as a non-profit network of health professionals, scientists and patient associations. ECLip aims to promote international collaborations to increase pathophysiological and clinical knowledge, and improve the management of lipodystrophy syndromes. ECLip now comprises 59 groups from 30 countries from Europe and beyond. The consortium developed in parallel to the increased awareness of clinical diagnosis, the growing scientific interest for these diseases at the crossroads between adipose tissue biology, whole body metabolism, genetics and immunity, and to the emergence of new pharmacological approaches. The ECLip congress, held every 18 months, aims to discuss the recent achievements and projects in the field of lipodystrophies, to consolidate ECLip activities and to promote future collaborations, highlighting clinical and fundamental aspects as well as patients' perspectives. Oral communications presented during the meeting in Paris, France, in 2025 are summarized in these minutes.